Vingraf IP 0.5mg

Name: Vingraf IP 0.5mg
Brand: BHAVYA ENTERPRISES
Price: 150 INR
Availability: InStock

Price 150 INR/ Pack

Get a Price/Quote

MOQ : 100 Packs

Vingraf IP 0.5mg Specification

Brand Name
Vingraf

Dosage Form
Capsule

Pacakaging (Quantity Per Box)
6x10 Capsules

Life Span
2 Years

Indication
Prevention of organ rejection

Packaging Type
Box

Salt Composition
Tacrolimus

Origin of Medicine
India

Drug Type
Allopathic

Ingredients
Tacrolimus 0.5mg

Physical Form
Capsule

Function
Immunosuppressant

Recommended For
Kidney, heart, liver transplant patients

Dosage
As directed by physician

Dosage Guidelines
Take on empty stomach

Suitable For
Adults

Quantity
60 capsules per box

Storage Instructions
Store below 25C

Capsule Color
White

Strength
0.5 mg

Route of Administration
Oral

Blister Pack
Yes

Formulation
Solid oral

Primary Use
Transplant rejection prevention

Prescription Required
Yes

Vingraf IP 0.5mg Trade Information

Minimum Order Quantity
100 Packs

Payment Terms
Cash in Advance (CID)

Supply Ability
5000 Packs Per Month

Delivery Time
2-10 Days

Main Domestic Market
All India

About Vingraf IP 0.5mg

Experience the sizzling new savings offered by Vingraf IP 0.5mg, the premier immunosuppressant for the valorous battle against transplant rejection. Featuring a sterling formulation with Tacrolimus 0.5mg, each pristine white capsule is meticulously designed for adult patients post kidney, heart, or liver transplantation. With a prescription, these solid oral capsules ensure efficacy, housed securely in a 6x10 blister pack-ready to support your health journey. Manufactured in India, Vingraf IP guarantees optimal organ protection, lasting potency for up to 2 years when stored below 25C, and is your trusted allopathic ally.

Vingraf IP 0.5mg: Exceptional Features and Versatile Application

Vingraf IP 0.5mg stands out for its swift, robust immunosuppressive action, targeted for preventing transplant rejection in adults. Its extra features include stable, reliable dosage delivery and user-friendly packaging. Beyond kidney, heart, and liver transplants, it can be considered in protocols for other complex transplants as determined by a healthcare provider. The formulation's flexibility supports post-surgical recovery, ensuring patients benefit from a secure, steadfast defense against immune complications.

Trade Information: FOB Port, Shipping, and Domestic Market

With every order completion, Vingraf IP 0.5mg is packaged carefully in boxes containing 60 capsules (6x10 blister packs) and shipped through major Indian FOB ports for efficient distribution. For clients wishing to assess quality, a sample policy is available upon request. The main domestic market spans across India, where deliveries are promptly arranged and packaging integrity is maintained, guaranteeing each shipment arrives in pristine condition to meet urgent clinical needs.

FAQ's of Vingraf IP 0.5mg:

Q: How should Vingraf IP 0.5mg capsules be administered?

A: Vingraf IP 0.5mg capsules are administered orally, ideally on an empty stomach, as directed by your physician to ensure optimal absorption and therapeutic effect.

Q: What is the primary benefit of using Vingraf IP 0.5mg?

A: The main benefit of Vingraf IP 0.5mg is its effective prevention of organ rejection in adults who have undergone kidney, heart, or liver transplants, helping prolong graft survival.

Q: When should patients take Vingraf IP 0.5mg?

A: Patients should take Vingraf IP 0.5mg at times specified by their healthcare provider and preferably on an empty stomach to maximize the drug's efficacy and maintain consistent blood levels.

Q: Where is Vingraf IP 0.5mg manufactured and available for supply?

A: Vingraf IP 0.5mg is manufactured in India and is supplied widely across the Indian domestic market, with shipping available from major FOB ports.

Q: What process secures Vingraf IP 0.5mg for transplant patients?

A: Vingraf IP 0.5mg requires a valid medical prescription and is dispensed in secure blister packaging, ensuring quality and tamper protection for transplant patients.